👤 Elke H Heiss

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
7
Articles
4
Name variants
Also published as: Christina N Heiss, G Heiss, Gerardo Heiss
articles
Christina N Heiss, Andrew S Naylor, Ida Pesämaa +11 more · 2026 · Frontiers in aging neuroscience · Frontiers · added 2026-04-24
Microglia, the resident immune cells of the central nervous system (CNS), play a pivotal role in health and disease maintaining homeostasis and mediating neuroinflammatory responses. Their activation Show more
Microglia, the resident immune cells of the central nervous system (CNS), play a pivotal role in health and disease maintaining homeostasis and mediating neuroinflammatory responses. Their activation is a dynamic and context-dependent process characterized by diverse phenotypic states defined by transcriptomic, proteomic, and morphological characteristics. While lipopolysaccharide (LPS) is widely used as an inflammatory stimulus in microglial research, its physiological relevance remains debated. Interferon gamma (IFNγ), a key pro-inflammatory cytokine involved in immune priming, more closely mimics CNS inflammatory conditions. In this study, we systematically investigated the temporal activation profiles of human iPSC-derived microglia (hiMG) in response to LPS, IFNγ, and their combination. Transcriptomic analysis at 24 h revealed robust differential gene expression, with over 7,000 genes altered by LPS and more than 8,500 by LPS/IFNγ co-stimulation. These profiles partially overlapped with disease-associated microglia (DAM) signatures, including upregulation of Show less
📄 PDF DOI: 10.3389/fnagi.2026.1756410
APOE
Dongdong Wang, Verena Hiebl, Daniel Schachner +4 more · 2020 · Biochemical pharmacology · Elsevier · added 2026-04-24
Increased cholesterol efflux from macrophage foam cells in the subendothelial space confers protection against atherosclerosis. Soraphen A, a myxobacterial macrolactone, is an inhibitor of acetyl coen Show more
Increased cholesterol efflux from macrophage foam cells in the subendothelial space confers protection against atherosclerosis. Soraphen A, a myxobacterial macrolactone, is an inhibitor of acetyl coenzyme A carboxylases (ACC), which control fatty acid synthesis and oxidation. To assess a potential direct link between macrophage cholesterol efflux and ACC inhibition, we examined [ Show less
no PDF DOI: 10.1016/j.bcp.2020.114022
NR1H3
Niha Zubair, Mariaelisa Graff, Jose Luis Ambite +54 more · 2016 · Human molecular genetics · Oxford University Press · added 2026-04-24
Genome-wide association studies have identified over 150 loci associated with lipid traits, however, no large-scale studies exist for Hispanics and other minority populations. Additionally, the geneti Show more
Genome-wide association studies have identified over 150 loci associated with lipid traits, however, no large-scale studies exist for Hispanics and other minority populations. Additionally, the genetic architecture of lipid-influencing loci remains largely unknown. We performed one of the most racially/ethnically diverse fine-mapping genetic studies of HDL-C, LDL-C, and triglycerides to-date using SNPs on the MetaboChip array on 54,119 individuals: 21,304 African Americans, 19,829 Hispanic Americans, 12,456 Asians, and 530 American Indians. The majority of signals found in these groups generalize to European Americans. While we uncovered signals unique to racial/ethnic populations, we also observed systematically consistent lipid associations across these groups. In African Americans, we identified three novel signals associated with HDL-C (LPL, APOA5, LCAT) and two associated with LDL-C (ABCG8, DHODH). In addition, using this population, we refined the location for 16 out of the 58 known MetaboChip lipid loci. These results can guide tailored screening efforts, reveal population-specific responses to lipid-lowering medications, and aid in the development of new targeted drug therapies. Show less
no PDF DOI: 10.1093/hmg/ddw358
APOA5
G Davies, N Armstrong, J C Bis +126 more · 2015 · Molecular psychiatry · Nature · added 2026-04-24
G Davies, N Armstrong, J C Bis, J Bressler, V Chouraki, S Giddaluru, E Hofer, C A Ibrahim-Verbaas, M Kirin, J Lahti, S J van der Lee, S Le Hellard, T Liu, R E Marioni, C Oldmeadow, I Postmus, A V Smith, J A Smith, A Thalamuthu, R Thomson, V Vitart, J Wang, L Yu, L Zgaga, W Zhao, R Boxall, S E Harris, W D Hill, D C Liewald, M Luciano, H Adams, D Ames, N Amin, P Amouyel, A A Assareh, R Au, J T Becker, A Beiser, C Berr, L Bertram, E Boerwinkle, B M Buckley, H Campbell, J Corley, P L De Jager, C Dufouil, J G Eriksson, T Espeseth, J D Faul, I Ford, Generation Scotland, R F Gottesman, M E Griswold, V Gudnason, T B Harris, G Heiss, A Hofman, E G Holliday, J Huffman, S L R Kardia, N Kochan, D S Knopman, J B Kwok, J-C Lambert, T Lee, G Li, S-C Li, M Loitfelder, O L Lopez, A J Lundervold, A Lundqvist, K A Mather, S S Mirza, L Nyberg, B A Oostra, A Palotie, G Papenberg, A Pattie, K Petrovic, O Polasek, B M Psaty, P Redmond, S Reppermund, J I Rotter, H Schmidt, M Schuur, P W Schofield, R J Scott, V M Steen, D J Stott, J C van Swieten, K D Taylor, J Trollor, S Trompet, A G Uitterlinden, G Weinstein, E Widen, B G Windham, J W Jukema, A F Wright, M J Wright, Q Yang, H Amieva, J R Attia, D A Bennett, H Brodaty, A J M de Craen, C Hayward, M A Ikram, U Lindenberger, L-G Nilsson, D J Porteous, K Räikkönen, I Reinvang, I Rudan, P S Sachdev, R Schmidt, P R Schofield, V Srikanth, J M Starr, S T Turner, D R Weir, J F Wilson, C van Duijn, L Launer, A L Fitzpatrick, S Seshadri, T H Mosley, I J Deary Show less
General cognitive function is substantially heritable across the human life course from adolescence to old age. We investigated the genetic contribution to variation in this important, health- and wel Show more
General cognitive function is substantially heritable across the human life course from adolescence to old age. We investigated the genetic contribution to variation in this important, health- and well-being-related trait in middle-aged and older adults. We conducted a meta-analysis of genome-wide association studies of 31 cohorts (N=53,949) in which the participants had undertaken multiple, diverse cognitive tests. A general cognitive function phenotype was tested for, and created in each cohort by principal component analysis. We report 13 genome-wide significant single-nucleotide polymorphism (SNP) associations in three genomic regions, 6q16.1, 14q12 and 19q13.32 (best SNP and closest gene, respectively: rs10457441, P=3.93 × 10(-9), MIR2113; rs17522122, P=2.55 × 10(-8), AKAP6; rs10119, P=5.67 × 10(-9), APOE/TOMM40). We report one gene-based significant association with the HMGN1 gene located on chromosome 21 (P=1 × 10(-6)). These genes have previously been associated with neuropsychiatric phenotypes. Meta-analysis results are consistent with a polygenic model of inheritance. To estimate SNP-based heritability, the genome-wide complex trait analysis procedure was applied to two large cohorts, the Atherosclerosis Risk in Communities Study (N=6617) and the Health and Retirement Study (N=5976). The proportion of phenotypic variation accounted for by all genotyped common SNPs was 29% (s.e.=5%) and 28% (s.e.=7%), respectively. Using polygenic prediction analysis, ~1.2% of the variance in general cognitive function was predicted in the Generation Scotland cohort (N=5487; P=1.5 × 10(-17)). In hypothesis-driven tests, there was significant association between general cognitive function and four genes previously associated with Alzheimer's disease: TOMM40, APOE, ABCG1 and MEF2C. Show less
📄 PDF DOI: 10.1038/mp.2014.188
AKAP6
Ron Do, Nathan O Stitziel, Hong-Hee Won +91 more · 2015 · Nature · Nature · added 2026-04-24
Ron Do, Nathan O Stitziel, Hong-Hee Won, Anders Berg Jørgensen, Stefano Duga, Pier Angelica Merlini, Adam Kiezun, Martin Farrall, Anuj Goel, Or Zuk, Illaria Guella, Rosanna Asselta, Leslie A Lange, Gina M Peloso, Paul L Auer, NHLBI Exome Sequencing Project, Domenico Girelli, Nicola Martinelli, Deborah N Farlow, Mark A DePristo, Robert Roberts, Alexander F R Stewart, Danish Saleheen, John Danesh, Stephen E Epstein, Suthesh Sivapalaratnam, G Kees Hovingh, John J Kastelein, Nilesh J Samani, Heribert Schunkert, Jeanette Erdmann, Svati H Shah, William E Kraus, Robert Davies, Majid Nikpay, Christopher T Johansen, Jian Wang, Robert A Hegele, Eliana Hechter, Winfried Marz, Marcus E Kleber, Jie Huang, Andrew D Johnson, Mingyao Li, Greg L Burke, Myron Gross, Yongmei Liu, Themistocles L Assimes, Gerardo Heiss, Ethan M Lange, Aaron R Folsom, Herman A Taylor, Oliviero Olivieri, Anders Hamsten, Robert Clarke, Dermot F Reilly, Wu Yin, Manuel A Rivas, Peter Donnelly, Jacques E Rossouw, Bruce M Psaty, David M Herrington, James G Wilson, Stephen S Rich, Michael J Bamshad, Russell P Tracy, L Adrienne Cupples, Daniel J Rader, Muredach P Reilly, John A Spertus, Sharon Cresci, Jaana Hartiala, W H Wilson Tang, Stanley L Hazen, Hooman Allayee, Alex P Reiner, Christopher S Carlson, Charles Kooperberg, Rebecca D Jackson, Eric Boerwinkle, Eric S Lander, Stephen M Schwartz, David S Siscovick, Ruth McPherson, Anne Tybjaerg-Hansen, Goncalo R Abecasis, Hugh Watkins, Deborah A Nickerson, Diego Ardissino, Shamil R Sunyaev, Christopher J O'Donnell, David Altshuler, Stacey Gabriel, Sekar Kathiresan Show less
Myocardial infarction (MI), a leading cause of death around the world, displays a complex pattern of inheritance. When MI occurs early in life, genetic inheritance is a major component to risk. Previo Show more
Myocardial infarction (MI), a leading cause of death around the world, displays a complex pattern of inheritance. When MI occurs early in life, genetic inheritance is a major component to risk. Previously, rare mutations in low-density lipoprotein (LDL) genes have been shown to contribute to MI risk in individual families, whereas common variants at more than 45 loci have been associated with MI risk in the population. Here we evaluate how rare mutations contribute to early-onset MI risk in the population. We sequenced the protein-coding regions of 9,793 genomes from patients with MI at an early age (≤50 years in males and ≤60 years in females) along with MI-free controls. We identified two genes in which rare coding-sequence mutations were more frequent in MI cases versus controls at exome-wide significance. At low-density lipoprotein receptor (LDLR), carriers of rare non-synonymous mutations were at 4.2-fold increased risk for MI; carriers of null alleles at LDLR were at even higher risk (13-fold difference). Approximately 2% of early MI cases harbour a rare, damaging mutation in LDLR; this estimate is similar to one made more than 40 years ago using an analysis of total cholesterol. Among controls, about 1 in 217 carried an LDLR coding-sequence mutation and had plasma LDL cholesterol > 190 mg dl(-1). At apolipoprotein A-V (APOA5), carriers of rare non-synonymous mutations were at 2.2-fold increased risk for MI. When compared with non-carriers, LDLR mutation carriers had higher plasma LDL cholesterol, whereas APOA5 mutation carriers had higher plasma triglycerides. Recent evidence has connected MI risk with coding-sequence mutations at two genes functionally related to APOA5, namely lipoprotein lipase and apolipoprotein C-III (refs 18, 19). Combined, these observations suggest that, as well as LDL cholesterol, disordered metabolism of triglyceride-rich lipoproteins contributes to MI risk. Show less
📄 PDF DOI: 10.1038/nature13917
APOA5
Yashashwi Pokharel, Wensheng Sun, Linda M Polfus +6 more · 2015 · Atherosclerosis · Elsevier · added 2026-04-24
Lipoprotein-associated phospholipase A2 (LpPLA2) activity was associated with higher CHD risk in a meta-analysis, which was partly dependent on circulating lipid levels. Apolipoprotein C3 loss-of-func Show more
Lipoprotein-associated phospholipase A2 (LpPLA2) activity was associated with higher CHD risk in a meta-analysis, which was partly dependent on circulating lipid levels. Apolipoprotein C3 loss-of-function (ApoC3 LOF) mutations were related with reduced postprandial lipemia and CHD risk. However, the association of LpPLA2 activity with ApoC3 LOF is not known. We examined the association of LpPLA2 activity and ApoC3 LOF mutations and incident cardiovascular disease (CVD) (defined as coronary heart disease [CHD] plus ischemic stroke) and all-cause mortality in the biracial longitudinal Atherosclerosis Risk In Communities (ARIC) study. The mean LpPLA2 activity was 229.3 nmol/min/mL and was higher in men and whites. LpPLA2 activity correlated positively with atherogenic dyslipidemia. ApoC3 LOF carriers had lower LpPLA2 activity levels compared to non-carriers, and there was inverse association between LpPLA2 activity and ApoC3 LOF mutations in whites. In a fully adjusted model, greater LpPLA2 activity was independently associated with incident CVD (HR 1.35, 1.09-1.68 for highest vs. lowest quintile), which was mainly explained by its association with CHD, and was also associated with all-cause mortality (HR 1.65, 1.38-1.98). Greater LpPLA2 activity was associated with increased CHD and all-cause mortality in both whites and African-Americans in the ARIC study. The inverse relation between LpPLA2 activity and ApoC3 LOF mutations suggests that delayed lipoprotein clearance may at least in part explain the observed association of LpPLA2 activity with increased CVD risk. Show less
📄 PDF DOI: 10.1016/j.atherosclerosis.2015.06.033
APOC3
Coffee and Caffeine Genetics Consortium, Marilyn C Cornelis, Enda M Byrne +155 more · 2015 · Molecular psychiatry · Nature · added 2026-04-24
Coffee and Caffeine Genetics Consortium, Marilyn C Cornelis, Enda M Byrne, Tõnu Esko, Michael A Nalls, Andrea Ganna, Nina Paynter, Keri L Monda, Najaf Amin, Krista Fischer, Frida Renstrom, Julius S Ngwa, Ville Huikari, Alana Cavadino, Ilja M Nolte, Alexander Teumer, Kai Yu, Pedro Marques-Vidal, Rajesh Rawal, Ani Manichaikul, Mary K Wojczynski, Jacqueline M Vink, Jing Hua Zhao, George Burlutsky, Jari Lahti, Vera Mikkilä, Rozenn N Lemaitre, Joel Eriksson, Solomon K Musani, Toshiko Tanaka, Frank Geller, Jian'an Luan, Jennie Hui, Reedik Mägi, Maria Dimitriou, Melissa E Garcia, Weang-Kee Ho, Margaret J Wright, Lynda M Rose, Patrik Ke Magnusson, Nancy L Pedersen, David Couper, Ben A Oostra, Albert Hofman, Mohammad Arfan Ikram, Henning W Tiemeier, Andre G Uitterlinden, Frank Ja van Rooij, Inês Barroso, Ingegerd Johansson, Luting Xue, Marika Kaakinen, Lili Milani, Chris Power, Harold Snieder, Ronald P Stolk, Sebastian E Baumeister, Reiner Biffar, Fangyi Gu, François Bastardot, Zoltán Kutalik, David R Jacobs, Nita G Forouhi, Evelin Mihailov, Lars Lind, Cecilia Lindgren, Karl Michaëlsson, Andrew Morris, Majken Jensen, Kay-Tee Khaw, Robert N Luben, Jie Jin Wang, Satu Männistö, Mia-Maria Perälä, Mika Kähönen, Terho Lehtimäki, Jorma Viikari, Dariush Mozaffarian, Kenneth Mukamal, Bruce M Psaty, Angela Döring, Andrew C Heath, Grant W Montgomery, Norbert Dahmen, Teresa Carithers, Katherine L Tucker, Luigi Ferrucci, Heather A Boyd, Mads Melbye, Jorien L Treur, Dan Mellström, Jouke Jan Hottenga, Inga Prokopenko, Anke Tönjes, Panos Deloukas, Stavroula Kanoni, Mattias Lorentzon, Denise K Houston, Yongmei Liu, John Danesh, Asif Rasheed, Marc A Mason, Alan B Zonderman, Lude Franke, Bruce S Kristal, International Parkinson’s Disease Genomics Consortium (IPDGC), North American Brain Expression Consortium (NABEC), UK Brain Expression Consortium (UKBEC), Juha Karjalainen, Danielle R Reed, Harm-Jan Westra, Michele K Evans, Danish Saleheen, Tamara B Harris, George Dedoussis, Gary Curhan, Michael Stumvoll, John Beilby, Louis R Pasquale, Bjarke Feenstra, Stefania Bandinelli, Jose M Ordovas, Andrew T Chan, Ulrike Peters, Claes Ohlsson, Christian Gieger, Nicholas G Martin, Melanie Waldenberger, David S Siscovick, Olli Raitakari, Johan G Eriksson, Paul Mitchell, David J Hunter, Peter Kraft, Eric B Rimm, Dorret I Boomsma, Ingrid B Borecki, Ruth Jf Loos, Nicholas J Wareham, Peter Vollenweider, Neil Caporaso, Hans Jörgen Grabe, Marian L Neuhouser, Bruce Hr Wolffenbuttel, Frank B Hu, Elina Hyppönen, Marjo-Riitta Järvelin, L Adrienne Cupples, Paul W Franks, Paul M Ridker, Cornelia M Van Duijn, Gerardo Heiss, Andres Metspalu, Kari E North, Erik Ingelsson, Jennifer A Nettleton, Rob M Van Dam, Daniel I Chasman Show less
Coffee, a major dietary source of caffeine, is among the most widely consumed beverages in the world and has received considerable attention regarding health risks and benefits. We conducted a genome- Show more
Coffee, a major dietary source of caffeine, is among the most widely consumed beverages in the world and has received considerable attention regarding health risks and benefits. We conducted a genome-wide (GW) meta-analysis of predominately regular-type coffee consumption (cups per day) among up to 91,462 coffee consumers of European ancestry with top single-nucleotide polymorphisms (SNPs) followed-up in ~30 062 and 7964 coffee consumers of European and African-American ancestry, respectively. Studies from both stages were combined in a trans-ethnic meta-analysis. Confirmed loci were examined for putative functional and biological relevance. Eight loci, including six novel loci, met GW significance (log10Bayes factor (BF)>5.64) with per-allele effect sizes of 0.03-0.14 cups per day. Six are located in or near genes potentially involved in pharmacokinetics (ABCG2, AHR, POR and CYP1A2) and pharmacodynamics (BDNF and SLC6A4) of caffeine. Two map to GCKR and MLXIPL genes related to metabolic traits but lacking known roles in coffee consumption. Enhancer and promoter histone marks populate the regions of many confirmed loci and several potential regulatory SNPs are highly correlated with the lead SNP of each. SNP alleles near GCKR, MLXIPL, BDNF and CYP1A2 that were associated with higher coffee consumption have previously been associated with smoking initiation, higher adiposity and fasting insulin and glucose but lower blood pressure and favorable lipid, inflammatory and liver enzyme profiles (P<5 × 10(-8)).Our genetic findings among European and African-American adults reinforce the role of caffeine in mediating habitual coffee consumption and may point to molecular mechanisms underlying inter-individual variability in pharmacological and health effects of coffee. Show less
📄 PDF DOI: 10.1038/mp.2014.107
MLXIPL